Seeing Is Believing
Currently out of the existing stock ratings of Geoff Meacham, 194 are a BUY (58.43%), 108 are a HOLD (32.53%), 30 are a SELL (9.04%).
Analyst Geoff Meacham, currently employed at BAML, carries an average stock price target met ratio of 66.73% that have a potential upside of 29.62% achieved within 226 days. Previously, Geoff Meacham worked at CITI.
Geoff Meacham’s has documented 645 price targets and ratings displayed on 51 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on BBIO, BridgeBio Pharma at 25-Nov-2024.
Analyst best performing recommendations are on OMER (OMEROS).
The best stock recommendation documented was for PTCT (PTC THERAPEUTICS) at 8/8/2018. The price target of $43 was fulfilled within 1 day with a profit of $2.28 (5.6%) receiving and performance score of 55.99.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
3 years 7 months 2 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
3 years 7 months 4 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
$7.5 (4.11%)
$194
3 years 10 months 3 days ago
(04-Feb-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
3 years 10 months 3 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
3 years 11 months ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Geoff Meacham is most bullish on?
Which stock is Geoff Meacham is most reserved on?
What Year was the first public recommendation made by Geoff Meacham?